News

Welcome to the CLINUVEL News page. Discover the latest in clinical, corporate, and regulatory updates.

SCENESSE® dosage expansion under review by European Medicines Agency

2024 Announcements.Clinical.News.Regulatory

20.11.2024

CLINUVEL prioritises three strategic programs

2024 Announcements . Clinical . News . Regulatory

18.11.2024

Bell Potter Healthcare Conference Presentation

2024 Announcements . Corporate . News

18.11.2024

Appendix 3Z – Final Director’s Interest Notice

2024 Announcements . Financial . News . Regulatory

17.10.2024

Results of Annual General Meeting 2024

2024 Announcements . Corporate . News

16.10.2024

Managing Director’s presentation

2024 Announcements . Corporate . News

16.10.2024

Chair’s address

2024 Announcements . Corporate . News

16.10.2024

Appendix 3Y Cover Note

2024 Announcements . Financial . News . Regulatory

03.10.2024

Appendix 3C – Notification of buy-back

2024 Announcements . Financial . News . Regulatory

02.10.2024

CLINUVEL files Canadian New Drug Submission for SCENESSE^® in EPP

2024 Announcements . Clinical . News . Regulatory

01.10.2024

Appendix 3C – Notification of buy-back

2024 Announcements . Financial . News . Regulatory

27.09.2024

Appendix 3C – Notification of buy-back

2024 Announcements . Financial . News . Regulatory

26.09.2024

SCENESSE^® data to be presented at global porphyria conference

2024 Announcements . Clinical . News . Regulatory

20.09.2024

.

Go To Top